Genetic Polymorphisms of Drug Metabolism
- 1 January 1990
- book chapter
- Published by Elsevier
Abstract
No abstract availableThis publication has 94 references indexed in Scilit:
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- The P450 Gene Superfamily: Recommended NomenclatureDNA, 1987
- Liver disease associated with anti-liver-kidney microsome antibody in childrenThe Journal of Pediatrics, 1986
- Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidationJournal of Molecular Medicine, 1985
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Inherited Defects of Hepatic Drug MetabolismSeminars in Liver Disease, 1983
- Seroimmunologic Classification of Chronic Hepatitis in 57 ChildrenHepatology, 1983
- Ethnic Differences in Drug MetabolismClinical Pharmacokinetics, 1982
- Disease and Acetylation PolymorphismClinical Pharmacokinetics, 1977